Navigation Links
Anaheim to Host World's Largest Gathering on Cystic Fibrosis Research and Care
Date:11/1/2011

BETHESDA, Md., Nov. 1, 2011 /PRNewswire-USNewswire/ --  For the first time, a drug that's designed to treat the underlying cause of cystic fibrosis, Kalydeco™ (ivacaftor), is under review by the U.S. Food and Drug Administration for possible approval in 2012. This milestone comes as the largest international gathering of cystic fibrosis experts kicks off in Anaheim, Calif., Nov. 3 – 5, 2011.

Kalydeco (kuh-LYE-deh-koh) is designed to address the genetic defect in cystic fibrosis in select patient groups, unlike all CF therapies now on the market, which only treat symptoms of the disease. It was formerly known as VX-770.

At the 25th annual North American Cystic Fibrosis Conference (NACFC), physicians, scientists and clinicians will present data and workshops on the latest advancements in CF related to research, care and drug development, including new clinical data on Kalydeco.

Key conference topics include:

  • Emerging therapies that target the core defect in CF.
  • Partnering with patients and families to improve care.
  • Best practices and mentoring for adult CF care providers.
  • Effective treatment and management of lung infections.

Cystic fibrosis is a genetic disease that causes life-threatening lung infections and premature death. An estimated 30,000 people in the United States, and about 70,000 people worldwide, have CF. Ten million Americans are symptomless carriers of a defective CF gene. Fifty years ago, most children with CF died before reaching kindergarten. Today, because of Cystic Fibrosis Foundation-supported drug research and care, many people with CF are living into their 30s, 40s and beyond.

WHAT:
The 25th Annual North American Cystic Fibrosis Conference, the largest international gathering of cystic fibrosis research scientists and clinicians.

WHEN & WHERE:
Thursday, Nov. 3 – Saturday, Nov. 5, 2011, at the Anaheim Convention Center, Anaheim, California.

KEYNOTE SPEAKERS:
Thursday, Nov. 3, 4:20 p.m. – Marcus A. Mall, M.D., University of Heidelberg, Heidelberg, Germany: "CFTR Modulation – 25 Years of NACFC Progress."

Friday, Nov. 4, 9:00 a.m. – Garry R. Cutting, M.D., and Patrick R. Sosnay, M.D., Johns Hopkins University, Baltimore, Maryland: "CFTR2 – A Research and Clinical Practice Tool."

Saturday, Nov. 5, 9:00 a.m. – Patrick A. Flume, M.D., Medical University of South Carolina, Charleston, South Carolina: "Pulmonary Exacerbations."

About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
5. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
6. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
7. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
8. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
9. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
10. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
11. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... , June 24, 2016 According ... by Type (Standard Pen Needles, Safety Pen Needles), Needle ... GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) - ... This report studies the market for the forecast period ... reach USD 2.81 Billion by 2021 from USD 1.65 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):